---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report. Covers Cost-effectiveness evidence. 10 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics/cost-effectiveness"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary

No cost-effectiveness or budget impact model of claseprubart has been published. The ICER evaluation, taking a health system perspective over a 2-year time horizon, estimated $5,210,000 per QALY/evLYG for eculizumab and $2,076,000 per QALY/evLYG for efgartigimod at a placeholder price, and the ratio was never less than $3.8 million per QALY/evLYG for eculizumab or $1.7 million per QALY/evLYG for efgartigimod when model inputs were changed. A Markov model with a lifetime horizon estimated $3,338,000 per QALY gained for eculizumab and $1,987,000 per QALY gained for efgartigimod. A 2026 network meta-analysis using 2026 US costs found efgartigimod IV had the lowest cost per improved outcome among six approved biologics. In Canada, efgartigimod dominated chronic immunoglobulin over a lifetime horizon, and in the United Kingdom thymectomy plus prednisolone dominated prednisolone alone. A study that included 31 articles reported considerable variability in the costs and cost-effectiveness of myasthenia gravis treatments across regions, therapies, and health care settings. The company's market assumption is an average biologic net price of approximately $400,000 per patient per year.

Source: [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/); [Lien et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144987/); [Smith et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42495790/); [Siddiqi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41139802/); [Lord et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13077509/); [Çipi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12836010/); [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-4.1-2"></a>

#### ICER evaluation of eculizumab and efgartigimod: model framing and base-case results

> “The analyses were framed to evaluate results over a 2-year time horizon, taking a health system perspective.”
> “For eculizumab, with an estimated annual cost of $653,100, the incremental cost-effectiveness ratio was $5,210,000 per QALY/evLYG (Table 2). For analyses of efgartigimod, we used a placeholder price of $418,400, which is the midpoint of the potential price range cited by the manufacturer.”
> “However, despite the large impact of changing these inputs on the results, the incremental cost-effectiveness ratio was never less than $3.8 million per QALY/evLYG for eculizumab and $1.7 million per QALY/evLYG for efgartigimod. In probabilistic sensitivity analyses, neither drug was ever found to reach cost-effectiveness at the $150,000 per QALY/evLYG threshold.”

Source: [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/)

<a id="topic-4.1-3"></a>

#### ICER health benefit price benchmarks and budget impact for eculizumab and efgartigimod

> “The HBPB range for eculizumab was estimated to be $13,200 to $19,400 (97%-98% discount from the Federal Supply Schedule [FSS] price). For efgartigimod, the HBPB range was estimated to be $18,300 to $28,400 (discounts not presented due to placeholder price) (Table ES2).”
> “The HBPB for a drug is defined as the drug price range that would achieve incremental cost-effectiveness ratios between $100,000 and $150,000 per QALY gained or per evLYG.”
> “In accordance with Figure 7.1, the percentage of the eligible population that can be treated with efgartigimod without passing the updated potential budget impact threshold is 8.8% at placeholder price ($418,000* per year).”

Source: [ICER (2021)](https://icer.org/wp-content/uploads/2021/03/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf)

<a id="topic-4.1-4"></a>

#### Lifetime U.S. cost-effectiveness of eculizumab and efgartigimod in AChR antibody-positive gMG

> “A Markov model with 4 health states was developed, evaluating costs and utility with a 4-week cycle length and lifetime time horizon from a health care system perspective and a modified societal perspective including productivity losses from patients and caregiver burden.”
> “Among the corresponding populations, lifetime costs and QALYs, respectively, for eculizumab were $5,515,000 and 11.85, and for conventional therapy, $308,000 and 10.29, resulting in an ICER of $3,338,000/QALY gained. For efgartigimod, lifetime costs and QALYs, respectively, were $6,773,000 and 13.22, and for conventional therapy, $322,000 and 9.98, yielding an ICER of $1,987,000/QALY gained.”
> “After applying indirect costs in a modified societal perspective, the ICERs were reduced to $3,310,000/QALY gained for eculizumab and $1,959,000/QALY gained for efgartigimod.”
> “To be considered cost-effective, eculizumab would need to be discounted by 93.01% and efgartigimod by 88.34% of the price that was used in the model’s base case.”

Source: [Lien et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144987/)

<a id="topic-4.1-5"></a>

#### Systematic review of health economic evaluations in myasthenia gravis

> “The study included 31 articles showing a considerable variability in the costs and cost-effectiveness of MG treatments across regions, therapies, and health care settings. Traditional therapies such as plasma exchange (PLEX) and intravenous immunoglobulin (IVIg) differ notably in cost, with PLEX generally being less expensive. Newer clinically effective treatments such as efgartigimod and eculizumab raise concerns about their economic sustainability, whereas rituximab might be a more affordable alternative in certain contexts.”

Source: [Çipi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12836010/)

<a id="topic-4.1-6"></a>

#### Cost per improved outcome of approved biologics: network meta-analysis with 2026 U.S. costs

> “A de novo NMA was performed using data from Phase III placebo-controlled trials of efgartigimod IV, inebilizumab, nipocalimab, ravulizumab, rozanolixizumab, and zilucoplan, including recently approved therapies.”
> “Cost per improved outcome (CPIO) was calculated using NNTs and 2026 US drug/administration costs.”
> “Efgartigimod IV had the lowest CPIO across all QMG and MG-ADL thresholds, significantly lower than almost all other treatments (p < 0.05).”

Source: [Smith et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42495790/)

<a id="topic-4.1-7"></a>

#### Canadian cost-utility analysis of efgartigimod compared with chronic immunoglobulin

> “The analysis was conducted from the perspective of the Canadian publicly funded healthcare system over a lifetime horizon.”
> “Over a lifetime horizon, efgartigimod and chronic immunoglobulins were predicted to have total discounted QALYs of 16.80 and 13.35 and total discounted costs of $1,913,294 and $2,170,315, respectively. Efgartigimod dominated chronic immunoglobulins with incremental QALYs of 3.45 and cost savings of $257,020.”

Source: [Siddiqi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41139802/)

<a id="topic-4.1-8"></a>

#### Cost-effectiveness of thymectomy in nonthymomatous myasthenia gravis: United Kingdom

> “The model adopted a UK NHS and Personal Social Services perspective over a lifetime horizon.”
> “In the base-case analysis, thymectomy plus prednisolone dominated prednisolone alone, yielding higher health gains (14.63 QALYs vs 14.11 QALYs) and lower lifetime costs (£181 716 vs £194 730). This generated an incremental gain of 0.52 QALYs and a cost saving of £13 014 per patient.”
> “These findings support current clinical guidelines recommending thymectomy for eligible patients and establish it as the most relevant comparator in evaluations of future health technologies.”

Source: [Lord et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13077509/)

<a id="topic-4.1-9"></a>

#### Cost per responder of intravenous immunoglobulin compared with molecular targeted drugs: Japan

> “The cost-effectiveness of IVIg and molecular targeted drugs was evaluated using cost per responder and cost per Myasthenia Gravis Activities of Daily Living (MG-ADL) improvement analyses.”
> “The cost per MG-ADL improvement was estimated at 7000-17,000 Japanese yen, which was substantially lower than that for molecular targeted drugs.”

Source: [Suzuki et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42275909/)

<a id="topic-4.1-10"></a>

#### Company market assumptions for claseprubart in generalized myasthenia gravis

> “The US gMG market has significant potential to expand as <20% of AChR+ patients”
> “Komodo claims data accessed 2013-2025, adjusted to account for 70% capture of real-world patient counts; AChR+ 85% of gMG.”
> “Assumes average biologic net price per patient of ~$400,000 per year.”
> “>$8B gMG Opportunity for Complement in 2035”
> “50% of the gMG market is anticipated to consist of branded biologics, driven by differentiated efficacy, safety and more convenient options”
> “Claseprubart has potential to capture meaningful market share across three synergistic multi-billion-dollar markets”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

No evidence found.

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
